Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.7K
1.7K
Tumor Immunotherapy01:27

Tumor Immunotherapy

2.1K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.5K
1.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

POLYAMINES AS NEW POTENTIAL BIOMARKERS FOR DIFFERENTIAL DIAGNOSIS OF PROSTATE CANCER AND ESTIMATION OF ITS AGGRESSIVENESS.

Experimental oncology·2022
Same author

Evaluation of response to tyrosine kinase inhibitors in renal cell carcinoma patients based on expression of miR-99b, -144, -210, -222, -302а and -377 in tumor tissue.

Experimental oncology·2021
Same author

Efficacy of Neoadjuvant Targeted Therapy in Treatment of Patients with Localised Clear-Cell Renal Cell Carcinoma.

Advances in urology·2021
Same author

Quality of life in patients after radical cystectomy with modified ureterocutaneostomy and Bricker urinary diversion.

Experimental oncology·2020
Same author

NANOG as prognostic factor of prostate cancer course.

Experimental oncology·2020
Same author

Expression pattern of genes associated with tumor microenvironment in prostate cancer.

Experimental oncology·2018

Related Experiment Video

Updated: Mar 23, 2026

Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy
11:27

Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy

Published on: April 29, 2014

17.3K

[NEOADJUVANT TARGET THERAPY IN A RENAL-CELL CANCER].

E O Stakhovskiy, O A Voylenko, O E Stakhovskiy

    Klinichna Khirurhiia
    |March 31, 2016
    PubMed
    Summary

    Neoadjuvant targeted therapy (NATTH) for renal-cell cancer (RCC) significantly reduced tumor size in 90% of patients. This approach facilitated organ-preserving surgery in 75% of localized RCC cases.

    More Related Videos

    A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
    06:38

    A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

    Published on: April 12, 2017

    14.4K
    The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers
    12:22

    The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers

    Published on: January 22, 2013

    34.2K

    Related Experiment Videos

    Last Updated: Mar 23, 2026

    Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy
    11:27

    Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy

    Published on: April 29, 2014

    17.3K
    A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
    06:38

    A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

    Published on: April 12, 2017

    14.4K
    The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers
    12:22

    The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers

    Published on: January 22, 2013

    34.2K

    Area of Science:

    • Oncology
    • Nephrology
    • Pharmacology

    Background:

    • Renal-cell cancer (RCC) presents significant treatment challenges.
    • Neoadjuvant therapy aims to improve surgical outcomes in RCC.
    • Targeted therapies offer novel approaches for managing localized and advanced RCC.

    Purpose of the Study:

    • To evaluate the efficacy of neoadjuvant targeted therapy (NATTH) in patients with renal-cell cancer (RCC).
    • To assess the impact of NATTH on tumor reduction and surgical intervention possibilities.
    • To determine the feasibility of organ-preserving treatment following NATTH for localized RCC.

    Main Methods:

    • A cohort of 30 patients (32 tumors) with RCC received neoadjuvant targeted therapy preoperatively.
    • Pazopanib (800 mg/day for 2 months) was administered to 19 patients.
    • Sunitinib (50 mg/day for 28 days, with 14-day breaks) was administered to 10 patients.

    Main Results:

    • NATTH resulted in primary pathological focus reduction in 90% of observed RCC cases.
    • Partial regression according to RECIST criteria was observed in 28.1% of patients.
    • Average tumor reduction of 22.9% enabled renal resection in 75% of localized RCC cases, preserving renal parenchyma.

    Conclusions:

    • Neoadjuvant targeted therapy is effective in reducing tumor size in renal-cell cancer.
    • NATTH enhances the possibility of performing organ-preserving surgery for localized RCC.
    • Targeted therapies like pazopanib and sunitinib show promise in the neoadjuvant setting for RCC management.